Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Corvus Pharmaceuticals and keeping the price target at $27.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sean Lee CFA has given his Buy rating due to a combination of factors tied to both clinical progress and financial positioning. He highlights that new biomarker data from the Phase 1 atopic dermatitis trial show soquelitinib is modulating key cytokines and immune regulators in a manner consistent with its mechanism of action, reinforcing confidence in its potential across multiple Th2/Th13-driven diseases and supporting the unchanged $27 price target.
He also points to evidence of durable clinical responses after treatment cessation, suggesting the possibility of “drug holidays” that could differentiate soquelitinib commercially versus incumbents like Dupixent and Rinvoq, which can exhibit rebound when stopped. In addition, he underscores a rich slate of 2026 catalysts across AD, PTCL, HS, and ALPS, and notes that Corvus’s cash balance of roughly $237M should fund operations through several of these value‑inflection points, thereby justifying a continued Buy stance.
According to TipRanks, Lee CFA is an analyst with an average return of -2.9% and a 28.76% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Dogwood Therapeutics, Alphatec Holdings, and Plus Therapeutics.
In another report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.